Facebook
Twitter
LinkedIn
Forward
This session will inform HCPs on the tirzepatide molecule, the SURMOUNT global trial program for the treatment of obesity and overweight, and the safety and efficacy data disclosure for SURMOUNT-3
|
CME/CE Expiration Date: 4/26/27*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
|
Poor responders to common medical weight loss treatments is a challenging situation for clinicians.
|
Treating obesity with bariatric surgery should be thought of as a starting point, not an end point. A key to success after bariatric surgery is the long-term postoperative management.
|
An important part of the Obesity Medicine provider’s practice, and one of the pillars of obesity care, is considering the use of medications for the treatment of overweight and obesity. Anti-obesi
|
As published and described in Obesity Pillars (i.e., the official journal of the Obesity Medicine Association), excessive weight reduction is an emerging challenge that sometimes arises with approv
|
OMA 2023 Spring Summit: Overcoming Barriers to Initiating Anti-Obesity Medications (On Demand)CME/CE Expiration Date: 4/23/26
|
A core component of obesity treatment includes recognition of weight promoting medications and their alternatives.
|
Recorded during Obesity Medicine 2022. CME/CE Expiration Date: 6/19/25
|
Dr. Weber will present and discuss case examples that will increase familiarity with antiobesity medication indications, contraindications, side effect profiles, and medication interactions.
|